Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, announced the launch of ZetaOmics, the computational biology module of its multi-agentic AI co-scientist platform, withZeta.ai. The platform introduces an autonomous “Computational Biologist” agent designed to perform end-to-end bioinformatics and multi-omic analysis across cancer types. Initially available through an early-access program for select academic, industry and company collaborators, the platform is designed to automate complex research workflows while embedding domain-specific intelligence intended to improve analytical rigor and reproducibility.
According to the company, ZetaOmics combines 14 specialized tools that can autonomously design, execute and validate biological analyses, detect potential flaws in experimental design and generate publication-quality results with a complete audit trail. Lantern said the platform expands withZeta.ai’s commercial opportunity beyond rare cancers by targeting academic medical centers, biotechnology and pharmaceutical companies, cancer centers and contract research organizations through subscription-based offerings and strategic collaborations.
The launch of ZetaOmics represents a significant step for Lantern Pharma as it seeks to monetize its AI capabilities beyond its internal drug development pipeline. The company’s proprietary RADR platform has been central to its precision oncology efforts, but withZeta.ai, launched earlier, and now ZetaOmics, Lantern is positioning itself as a provider of AI-driven research tools for the broader biomedical community. This move could open up new revenue streams, as the platform is available as a subscription-based research platform for the global biomedical and drug development community.
Lantern’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary. The company operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.
For researchers and institutions, ZetaOmics offers the potential to streamline bioinformatics workflows that are often time-consuming and prone to error. By automating data analysis and providing an audit trail, the platform could enhance reproducibility, a key challenge in computational biology. The early-access program will allow collaborators to test and refine the platform, potentially leading to wider adoption. The full press release is available at https://ibn.fm/9sIIl.
This development underscores the growing trend of AI integration in drug discovery and biomedical research. Lantern Pharma’s ability to leverage its AI expertise to create a commercial product could provide a competitive edge, while also contributing to the broader scientific community’s efforts to accelerate cancer research. The implications of ZetaOmics extend beyond Lantern’s own pipeline, potentially impacting how academic and industry researchers approach multi-omic analysis and bioinformatics.
